Stock Delisting: Deficiency Notices, Cure Periods, and Relisting

The stock delisting process is the sequence an exchange follows when a listed company falls out of compliance with continued listing standards: a private deficiency notice, a cure period to fix the problem, a compliance plan or hearing if the fix doesn’t come in time, and finally formal removal from the exchange through a Form 25 filing with the SEC. Nasdaq and the New York Stock Exchange each publish their own rules, but the arc is the same at both. Where the process ends matters as much as how it runs, because a delisted stock keeps existing — it just trades somewhere much less friendly to ordinary shareholders.

What Triggers the Process

Most delistings start with price. On Nasdaq, a company falls out of compliance once its closing bid price stays below $1.00 for 30 consecutive business days.¹ The NYSE uses a similar threshold, tied to an average closing price below $1.00 over a consecutive 30 trading-day period.² Market capitalization and the value of publicly held shares can also trigger a deficiency if they stay below minimum thresholds for 30 consecutive business days on Nasdaq.

A new NYSE rule takes effect on October 1, 2026: if a stock’s closing price drops below $0.25 on any single trading day, the exchange will immediately suspend trading and begin delisting procedures with no cure period at all.² That hard floor eliminates the normal remediation process for deeply distressed stocks.

Price is not the only trigger. Falling behind on required SEC filings, such as annual reports on Form 10-K or quarterly reports on Form 10-Q, sets off a deficiency of its own. On Nasdaq, the company has 60 calendar days to submit a plan to regain compliance, and the total exception period is capped at 180 calendar days from the due date of the first late filing. Governance failures — losing the required majority of independent directors, for example, or an audit committee that no longer meets composition rules — trigger their own timelines, generally running until the earlier of the next annual shareholders’ meeting or one year from the event.¹

When the exchange identifies a deficiency, it notifies the company in a private letter specifying the rule violated and the consequences of not fixing it.¹ The company must then disclose the notice publicly through a Form 8-K, generally within four business days.³ NYSE-listed domestic companies must also issue a press release within that same window.² That’s usually how shareholders learn the process has started.

The Cure Period

Once notified, the company gets a defined window to fix the problem. Nasdaq gives 180 calendar days from the initial notification to bring the closing bid price back to at least $1.00, and compliance is achieved by holding a closing bid price of $1.00 or more for a minimum of 10 consecutive business days during that window. Nasdaq staff can extend the observation beyond 10 days at their discretion.¹

The NYSE structures its cure period differently. A company has six months from receiving the notification, and it regains compliance if, on the last trading day of any calendar month during that period, the closing share price is at least $1.00 and the average closing price over the preceding 30 trading days also meets that threshold. The company must also tell the exchange within 10 business days of the deficiency letter that it intends to cure, or the exchange moves straight to suspension.²

Clearing the bar in time ends the matter: the exchange sends a letter confirming the company is back in good standing. Missing it moves the company into a more precarious phase. On Nasdaq, staff may grant an additional 180 calendar days, but only if the company can show a credible path back to compliance.¹ If that extension is denied or the company still can’t comply, the exchange issues a staff delisting determination — the formal notice that begins the countdown toward removal.

Reverse Stock Splits

The most common quick fix for a price deficiency is a reverse stock split. The company reduces the number of outstanding shares, which mathematically raises the per-share price: a 1-for-10 reverse split turns 1,000 shares into 100 at roughly 10 times the pre-split price. Reverse splits require shareholder approval, so the company either holds a special meeting or waits for the next annual meeting.

NYSE rules accommodate this path explicitly. A company that plans to cure through a reverse split must tell the exchange within 10 business days of the deficiency notice, obtain shareholder approval by its next annual meeting, and implement the split promptly afterward. The price must then exceed $1.00 and stay above it for at least 30 trading days.²

Repeat splits have gotten harder. On the NYSE, a company is ineligible for a cure period if it has already done a reverse split in the prior year, or if its cumulative reverse-split ratio over the prior two years reaches 200-to-1 or higher. In those cases the exchange skips straight to suspension and delisting. A reverse split also can’t leave the company below the exchange’s minimum distribution requirements; if it does, delisting proceedings begin immediately.⁴

Compliance Plans, Hearings, and Appeals

When a company can’t cure a deficiency inside the standard window, it has to convince the exchange that compliance is still achievable. On the NYSE, domestic companies have 45 days from the deficiency letter to submit a formal plan; non-U.S. companies get 90 days. The plan must include quarterly milestones for domestic companies and semi-annual milestones for non-U.S. companies.⁵

One detail catches companies out: the NYSE will not review a compliance plan at all if the company has unpaid listing or annual fees. Those must be paid in full before the submission deadline, or the exchange moves directly to suspension and delisting. The fee obligation continues through the plan period, with quarterly checks.⁵

Effective compliance plans include financial projections backed by audited statements, evidence of capital-raising efforts, planned asset divestitures or other strategic actions, and any corporate transactions in the pipeline. Vague promises don’t survive staff review.

On Nasdaq, once staff issues a delisting determination, the company has seven calendar days to request a hearing before an independent panel.¹ The request carries a non-refundable hearing fee of $20,000.⁶ A timely hearing request generally stays the suspension and delisting action, keeping the stock tradable while review proceeds. The panel has at least two members authorized by the Nasdaq Board, none of whom can be Nasdaq employees or affiliates; anyone with a conflict must recuse.

A favorable panel ruling can grant an exception period of up to 180 days from the staff determination, with specific milestones the company must hit. An unfavorable ruling means the stock is suspended and delisting moves forward, with the stay ending the moment the decision is issued.¹

A panel decision isn’t necessarily the end. On Nasdaq, the company can appeal to the Listing and Hearing Review Council within 15 calendar days by submitting a written request and a non-refundable $15,000 fee. The Listing Council can also initiate its own review of a panel decision within 45 calendar days. An appeal to the Listing Council does not stay the panel’s decision, so the stock can be suspended while the appeal is pending.¹

After exhausting the exchange’s internal appeals, a company can petition the SEC for review under Section 19(d) of the Securities Exchange Act. The SEC reviews the exchange’s decision on a de novo basis. If that is also unfavorable, the last option is the U.S. Court of Appeals.⁷ In practice, very few companies pursue appeals past the exchange level.

Formal Removal from the Exchange

Once the process concludes, the exchange files Form 25 with the SEC. The delisting becomes effective 10 days after the filing. Withdrawal of the company’s registration under Section 12(b) of the Exchange Act follows 90 days later, unless the SEC sets a shorter period.⁸ The exchange must attach a copy of its delisting determination to the Form 25 filing on EDGAR.⁷

Delisting from an exchange does not automatically end SEC reporting obligations. Those continue as long as the company meets the thresholds for registration under Section 12(g). A company can terminate reporting duties by filing Form 15, but only if its shares are held by fewer than 300 holders of record — or fewer than 500 holders if total assets have not exceeded $10 million in each of the three most recent fiscal years.⁹ Companies above those thresholds keep filing 10-Ks, 10-Qs, and 8-Ks even after their stock leaves the exchange.

What Delisting Means for Your Shares

Delisting does not make your shares disappear. You still own them, and the company still exists. What changes is where and how easily you can trade them. Most delisted stocks move to the over-the-counter markets operated by OTC Markets Group, which sorts securities into tiers based on the company’s disclosure and financial health.

The practical impact is severe. Research on delisted securities shows that trading volume typically drops by roughly two-thirds, bid-ask spreads more than double, and price volatility increases sharply. Mutual funds, pension funds, and index trackers often face internal mandates or prospectus restrictions that prevent them from holding OTC stocks, which forces additional selling and pushes prices down further.

Margin treatment changes too. Under Federal Reserve Regulation T, a “margin security” includes securities registered on a national exchange or listed on Nasdaq. A delisted stock loses that status and only qualifies as marginable again if the Federal Reserve separately designates it as an OTC margin stock, which requires sufficient national investor interest, market depth, and issuer permanence. Most delisted stocks don’t meet that bar, so brokers will limit you to a cash account for further purchases. Existing margin positions won’t necessarily be liquidated, since the regulation allows maintenance of credit initially extended in compliance, but your broker may still require additional deposits or closures under its own house margin policies.¹⁰

OTC Markets Group operates three tiers: OTCQX (highest), OTCQB (the venture market), and Pink (lowest). Delisted companies that still file with the SEC often land on OTCQB, which requires continued SEC reporting, GAAP financial statements audited by a PCAOB-registered auditor, a minimum bid price of $0.01 on an ongoing basis, at least 50 beneficial shareholders each holding 100 or more shares, and a minimum 10% public float. Companies in bankruptcy are ineligible for OTCQB.¹¹ Companies that can’t meet those standards trade on Pink, where disclosure is minimal and liquidity is often razor-thin.

Coming Back to a National Exchange

Re-listing is possible, but exchanges treat previously delisted companies with heightened scrutiny. Nasdaq retains broad discretionary authority to deny a listing application even when a company meets every published standard, if it determines the listing would be “inadvisable or unwarranted.” That review can consider governance conduct during the period the company was not listed.¹²

Most delisted companies never come back. The financial distress that led to delisting rarely resolves quickly, and the loss of institutional investors, analyst coverage, and public visibility is difficult to reverse. Companies that do return tend to have gone through significant restructuring, management changes, or new capital that fundamentally altered the business.

1
The Nasdaq Stock Market. Nasdaq Rule 5800 Series – Failure to Meet Listing Standards
2
U.S. Securities and Exchange Commission. NYSE Listed Company Manual – Exhibit 5
3
U.S. Securities and Exchange Commission. Form 8-K
4
U.S. Securities and Exchange Commission. NYSE Proposed Rule Change – Amendment No. 2
5
Federal Register. New York Stock Exchange LLC Notice of Filing of Amendment No. 1
6
U.S. Securities and Exchange Commission. Nasdaq Rule Filing 34-102474-ex5
7
U.S. Securities and Exchange Commission. Final Rule – Removal from Listing and Registration of Securities
8
eCFR. 17 CFR 240.12d2-2 – Removal from Listing and Registration
9
eCFR. 17 CFR 240.12g-4 – Certifications of Termination of Registration
10
eCFR. 12 CFR Part 220 – Credit by Brokers and Dealers (Regulation T)
11
OTC Markets Group. Eligibility Requirements – OTCQX, OTCQB
12
The Nasdaq Stock Market. Nasdaq Rule 5100 Series